KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis - PubMed
4 hours ago
- #KDM5B
- #Prostate Cancer
- #Enzalutamide Resistance
- KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer.
- The resistance mechanism involves the lactate/hnRNPA1 lactylation/AR-V7 axis.
- Study approved by the Medical Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.
- No competing interests declared by the authors.